ClinicalTrials.gg
RecruitingNCT07110896AnexLBUpdated Nov 6, 2026

Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults

An interventional study of Humiome Post LB (Postbiotic) and Placebo in Healthy Aging, sponsored by dsm-firmenich Switzerland AG. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

To assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria) Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo

Read the detailed description

A double-blinded, randomised and placebo-controlled study will be conducted to assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria), Humiome® Post LB, on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted for baseline in study participants when compared to placebo.

The study will be in healthy subjects who are getting older (ageing population) and will measure factors such as stress, sleep, anxiety as well as gut microbiome. The intervention period will be 90 days, and study will include 236 subjects in two arms (active and placebo),

02

Conditions studied

  • Healthy Aging

Browse trials for

Keywords

  • Healthy aging
  • Microbiome
  • Stress
  • Sleep
  • Anxiety
  • gut-brain
03

In context

Anxiety Disorders Unverified

7,238 studies on the registry are indexed under Anxiety Disorders; 1,687 are open to participants now.

This study's planned enrollment of 236 is above the median of 80 across 6,092 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is male or female, 50-75 years of age, inclusive.
  2. Participant has a (BMI) of ≥18.5 kg/m2 to 32 kg/m2.
  3. Participant is generally in good health, as per investigator's judgement at V1.
  4. Participant has subjective mild to moderate memory complaints, as per investigator's judgement.
  5. Participant has a total score of ≥42 and ≤60 on the DASS-21 administered at V1.
  6. Participant is willing to maintain regular dietary, exercise, and allowed medication/supplement habits and smoking and other nicotine habits (if a smoker or nicotine user) for the duration of the study.
  7. Participant understands the study procedures and signs forms documenting to participate in the study and authorization for release of relevant protected health information to the study investigator.

7. Participant understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.

Exclusion criteria

Exclusion criteria:

  1. Participant has a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disease, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other psychiatric/neurologic condition that, in the opinion of the investigator, could interfere with the interpretation of the study results.
  2. score at V1 \< 21.
  3. Chronic fatigue syndrome.
  4. Women: elevated stress and/or anxiety levels clearly related to the (peri) menopause complaints, as per investigator judgement
  5. Non-pharmacological or non-supplementation options for management of stress, anxiety or memory/cognitive complaints (e.g. yoga, "brain jogging") started within 4 weeks of screening 6. Participant has a clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder that, in the opinion of the investigator, could interfere with the interpretation of the study results.

7. Participant has a condition that would likely cause . 8. Participant has a history of gastrointestinal surgery (cholecystectomy and appendectomy are acceptable, considering the prevalence in the age group), as per investigator judgement. 9. Participant has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at screening.

10. Participant has an issue with hearing or seeing that might interfere with the tasks/questionnaires to be completed during the visits.

11. Participant has used pre-, pro-, syn-, or post-biotic supplements within 90 days of screening.

12. Participant has a history of using psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and/or narcotics within 4 weeks of screening. 13. Participants has major sleep disorder (severe insomnia) based on investigator's judgment.

14. Participant has used sleep aid medications, supplements, and/or products, including antihistamines, within 2 weeks of screening ( prior to screening is allowed). Sporadic use of supplementation of melatonin, valerian, passion flower, lavender, if needed, if this has been habitually or occasionally done prior to the study, is allowed. 15. Participant has used an acid-blocking medication (e.g., proton pump inhibitor, H2 blocker) in the past 30 days prior to study. However, any ongoing use started at least 12 weeks before Visit 1 is allowed.

16. Participant has used selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines in the past 30 days. (Note: Participants will not be excluded on the basis of a well-managed depressive disorder that does not require SSRIs.) 17. Participant has a history of cancer in the prior 5 years. 18. Participant has an allergy to any components of the IP or the standardized breakfast.

19. Individual has signs or symptoms of an active infection of clinical significance or has taken antibiotics within 30 days prior to any visit (washout is permitted for re-scheduling of the clinic visit).

20. Participant has been exposed to any non-registered drug product within 30 days of the screening visit.

21. Participant has a current or recent history (within 12 months of screening) or strong potential for illicit drug or excessive alcohol intake defined as >14 drinks per week (1 drink = 350 ml beer, 150 ml wine, or 40 ml hard liquor).

22. Women lactating, pregnant or of not using a reliable method.

23. Participant has a condition the investigator believes would interfere with his/her ability to provide , comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
236 participants (estimated)

Study arms

  • Active comparator
    Active

    Humiome Post LB (Postbiotic) : 340mg in 2 identical capsules per day orally

    Dietary Supplement: Humiome Post LB (Postbiotic)

  • Placebo comparator
    Placebo

    Microcrystalline in 2 identical capsules per day orally

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementHumiome Post LB (Postbiotic)

    Heat-inactivated lactobacilli with fermented medium (a postbiotic) in 340mg powder format

    Also known as: Lactobacillus LB

  • Dietary supplementPlacebo

    Microcrystalline cellulose, 340mg powder format

    Also known as: microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Effect on stress

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo

    Time frame: Timeframe - Day 0 (V2), and Day 90 (V4)

Secondary outcomes

  1. Effect on stress (adjusted to baseline)

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo. Lowest Value: 0, Highest Value: 42. A higher score means a worse outcome

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  2. Effect on stress (within the group)

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on change in DASS-21 subscores of stress, depression, anxiety in study participants when compared to placebo (between group comparison) and baseline (withingroup comparison). Lowest Value: 0, Highest Value: 42. A higher score means a worse outcome

    Time frame: (Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  3. Effect on stress (within the group, compared to baseline)

    To assess the effect of 3 months of daily consumption of Humiome® Post LB and Placebo on stress measured by the DASS-21 in study participants when compared to baseline. Lowest Value: 0, Highest Value: 42. A higher score means a worse outcome.

    Time frame: (Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  4. Effect on indicators of Anxiety

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of anxiety when compared to placebo and baseline . The GAD-7 total score (range 0-21, expressed in a.u.) will be used to assess indicators of anxiety. Lowest Value: 0 Highest Value: 21. A higher score means a worse outcome

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  5. Effect on indicators of perceived stress

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of perceived stress when compared to placebo and baseline. The PSS-10 total score (range 0-40; expressed in a.u.) will be used to assess indicators of perceived stress. Lowest Value: 0, Highest Value: 40. A higher score means a worse outcome,

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  6. Effect on Indicators of cognition and memory

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of cognition and memory when compared to placebo and baseline. Cogstate International Digit Symbol Substitution Test (symbols) will be used to test domains processing speed test, assesses focused attention and aspects of executive functioning; the outcome is the total number of correct responses

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  7. Effect on indicators of Chronic inflammation (hs-CRP) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Chronic inflammation in blood when compared to placebo and baseline. For this hs-CRP levels in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  8. Effect on indicators of Chronic inflammation (homocysteine) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this homocysteine levels in blood, will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  9. Effect on indicators of Chronic inflammation (BDNF) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this BDNF (brain-derived neurotrophic factor protein) in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  10. Effect on indicators of Chronic inflammation (IL-11) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this IL-11 levels in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  11. Effect on indicators of Chronic inflammation (IL-6) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this, IL-6 levels in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  12. Effect on indicators of Chronic inflammation (IL-10) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this IL-10 levels in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  13. Effect on indicators of Chronic inflammation (TNF-α) in blood

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in blood when compared to placebo and baseline. For this TNF-α levels in blood will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  14. Effect on indicators of Chronic inflammation in feces

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on indicators of Indicators of Chronic inflammation in feces when compared to placebo and baseline. For this Calprotectin levels in feces will be measured

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

Other outcomes

  1. Effect on Musculoskeletal strength

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on the Musculoskeletal strength when compared to placebo and baseline. Musculoskeletal strength will measured by grip strength using a hand dynamometer (dominant arm) (expressed in kg).

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  2. Effect on Visual-motor coordination

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Visual-motor coordination when compared to placebo and baseline. Visual-motor coordination of study participants (expressed in seconds) will be measured by the "Manipulation and Dexterity Test - Pegboard".

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  3. Effect on Indicators of general health and well-being

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Indicators of general health and well-being when compared to placebo and baseline. The SF-12 will be used to assess general health and well-being: physical component summary and mental component summary scales (T score, expressed in a.u.). Lowest Value: 0, Highest Value: 100. A higher score means a better outcome,

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  4. Effect on Indicators of sleeping quality status

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Indicators of sleeping quality status when compared to placebo and baseline. The PSQI global score will be used to assess sleep quality (expressed in a.u., range 0-21). Lowest Value: 0, Highest Value: 21. A higher score means a worse outcome

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  5. Effect on gastrointestinal function

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on gastrointestinal function when compared to placebo and baseline. The GSRS (Gastrointestinal Symptom Rating Scale) will be used to assess the participants' gastrointestinal function (5 subscores) (expressed in a.u., range 1-7)

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  6. Effect on Glycemic status (Blood insulin)

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Glycemic status when compared to placebo and baseline. For this, blood Insulin levels will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  7. Effect on Glycemic status (Glucose levels)

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Glycemic status when compared to placebo and baseline. For this, blood glucose levels will be measured.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  8. Effect on indicators of insulin resistance

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on insulin resistance when compared to placebo and baseline. For this (HOMA-IR technique) (expressed in a.u.) will be used.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  9. Effect on Blood lipid levels

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Blood lipid levels when compared to placebo (between group comparison) and baseline (within group comparison)

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  10. Effect on Body weight

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Body weight when compared to placebo (between group comparison) and baseline (within group comparison)

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  11. Effect on Microbiome composition

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Microbiome composition when compared to placebo and baseline. Microbiome composition will be measured using full shotgun sequencing.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  12. Effect on Microbiome diversity

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Microbiome diversity when compared to placebo and baseline. Microbiome diversity will be measured using full shotgun sequencing.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  13. Effect on fecal metabolomic profile

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on fecal metabolomic profile when compared to placebo and baseline. Metabolomic profile will be analyzed using semi-polar liquid chromatography-mass spectrometry (LC-MS)/MS method.

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

  14. Effect on Fecal organic acid levels

    To assess the effect of 3 months of daily consumption of Humiome® Post LB on Fecal organic acid levels when compared to placebo (between group comparison) and baseline (within group comparison)

    Time frame: Timeframe - Day 0 (V2), Day 45 (V3) and Day 90 (V4)

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.

Of 103 industry-sponsored interventional studies with no phase under Anxiety Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 18 months is above that.

Counting every sponsor, half of 3,969 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Oct 2026 → Feb 2027 and completion Nov 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Aug 8, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Feb 2027was Oct 2026
CompletionEst.
Feb 2027was Nov 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Feb 2027
Nov 6, 2026
Study completion
Nov 2026→Feb 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Oct 2026→Feb 2027
    Study completion Nov 2026→Feb 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07110896
Collaborators
Analyze & Realize
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 1, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Liana Vismane, DR
Contact
lvismane@a-r.com
+493040008122
Natalie Doberstein
Contact
ndoberstein@a-r.com
+493040008156
Mehdi Sadaghian, PhD
study director · dsm-firmenich Switzerland AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion